All In Biotech

Drug Trial Radar · NCT06836037

A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)

A Single and Multiple Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics of MK-6024 in Healthy Chinese Participants

Last checked: Nov 19, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Sep 5, 2022

Primary completion

Feb 2, 2023

Study completion Feb 2, 2023

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to learn about the safety and whether people tolerate a study medicine called efinopegdutide. The study will also measure what happens to efinopegdutide in a healthy person's body over time.

Conditions

  • Healthy

Interventions

  • EfinopegdutideDrug

    Subcutaneous injection

  • PlaceboDrug

    placebo matching efinopegdutide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 112 days
  2. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 78 days
  3. Maximum Plasma Concentration (Cmax) of Efinopegdutide- single doseTime frame: At designated time points up to 35 days
  4. Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- single doseTime frame: At designated time points up to 35 days
  5. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide- single doseTime frame: At designated timepoints up to 35 days
  6. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-inf) of Efinopegdutide- single doseTime frame: At designated timepoints up to 35 days
  7. Terminal half life (t1/2) of Efinopegdutide- single doseTime frame: At designated timepoints up to 35 days
  8. Apparent Clearance (CL) of Efinopegdutide- single doseTime frame: At designated timepoints up to 35 days
  9. Volume of Distribution (Vz) of Efinopegdutide- single doseTime frame: At designated timepoints up to 35 days
  10. Maximum Plasma Concentration (Cmax) of Efinopegdutide- multiple doseTime frame: At designated time points up to 112 days
  11. Minimum Plasma Concentration (Cmin) of Efinopegdutide- multiple doseTime frame: At designated time points up to 112 days
  12. Time to Maximum Plasma Concentration (Tmax) of Efinopegdutide- multiple doseTime frame: At designated time points up to 112 days
  13. Terminal half life (t1/2) of Efinopegdutide- multiple doseTime frame: At designated timepoints up to 112 days
  14. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Efinopegdutide-multiple doseTime frame: At designated timepoints up to 112 days
  15. Apparent Clearance (CL) of Efinopegdutide- multiple doseTime frame: At designated timepoints up to 112 days
  16. Volume of Distribution at Steady State (Vss) of Efinopegdutide- multiple doseTime frame: At designated timepoints up to 112 days
  17. Area Under the Concentration-Time Curve to the end of the dosing period (AUC 0-tau)of Efinopegdutide- multiple doseTime frame: At designated timepoints up to 78 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 0001)

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.